Targeting Phosphoinositide 3-Kinase – Five Decades of Chemical Space Exploration

Authors

DOI:

https://doi.org/10.2533/chimia.2021.1037

Keywords:

PI3K, mTOR, wortmannin, kinase inhibitors, Drug discovery

Abstract

Phosphoinositide 3-kinase (PI3K) takes a key role in a plethora of physiologic processes and controls cell growth, metabolism, immunity, cardiovascular and neurological function, and more. The discovery of wortmannin as the first potent PI3K inhibitor (PI3Ki) in the 1990s provided rapid identification of PI3K-dependent processes, which drove the assembly of the PI3K/protein kinase B (PKB/Akt)/target of rapamycin (mTOR) pathway. Genetic mouse models and first PI3K isoform-specific inhibitors pinpointed putative therapeutic applications. The recognition of PI3K as target for cancer therapy drove subsequently drug development. Here we provide a brief journey through the emerging roles of PI3K to the development of clinical PI3Ki candidates.

Downloads

Published

2021-12-09

How to Cite

[1]
C. Borsari, M. P. Wymann, Chimia 2021, 75, 1037, DOI: 10.2533/chimia.2021.1037.